Scope and claims analysis for US Patent 5,569,652: dihydrospirorenone methods combining gestagenic, antiandrogenic, and antialdosterone effects

US 5,569,652 is a US method-of-use patent anchored to a single active principle: administering dihydrospirorenone to a female patient during premenopause or menopause to achieve, simultaneously, three pharmacodynamic effects: gestagenic, antiandrogenic, and anti-aldosterone (claims 1, 11). Dependent claims narrow the patient population, dosing range, and optionally add an estrogenic compound (claims 11-27). The scope is broad across dosing (0.5-50 mg/day) and fairly specific on the “triple-effect” functional requirement and the hormonal state (premenopause or menopause).

Because the claims are method claims, the practical IP boundary for generics and competitors is whether their labeled or induced use in the US would fall within the “simultaneously achieving” functional language and the claimed hormonal-state/patient-profile limitations.

What are the independent claims in US Patent 5,569,652 and what do they require to infringe?

Claim 1: triple-effect method with dihydrospirorenone alone

Claim 1 is the main standalone infringement anchor:

Exerted during premenopause or menopause
Female patient “in need thereof”
Administer an amount of dihydrospirorenone effective to simultaneously achieve
1. gestagenic effect
2. antiandrogenic effect
3. antialdosterone effect

Key infringement elements embedded in the wording:

Functional triad requirement: the method is limited to regimens that produce all three effects “simultaneously.”
Actively required therapeutic context: “female patient… in need thereof” is a patient selection requirement, not a purely mechanistic limitation.
Timing/hormonal stage: premenopause or menopause limits the target use window.

Claim 11: triple-effect method with dihydrospirorenone plus an estrogenic compound

Claim 11 expands coverage to a combination regimen:

Administer dihydrospirorenone and an estrogenic compound
Achieve a contraceptive effect plus the same triple-effect triad (gestagenic, antiandrogenic, anti-aldosterone)
Again limited to premenopause/menopause

This creates two distinct claim “entry points” for competitors:

Dihydrospirorenone monotherapy use that achieves the triple triad (claim 1).
Combination therapy that achieves contraception plus the triple triad (claim 11).

How does the “simultaneously achieving” requirement narrow the claim scope?

The “simultaneously achieving” language is the core functional limiter. It affects scope in two ways:

It is not satisfied by regimens that achieve only one or two pharmacodynamic effects. A competitor that designs a use that emphasizes gestagenic and antiandrogenic effects but does not provide a functional antialdosterone effect would be outside the literal triad.
It requires linkage between the regimen and the three outcomes at the same time during the treatment course. In litigation, this typically shifts proof toward pharmacology evidence tied to dosing and use population.

From a freedom-to-operate perspective, this functional language can be attacked or defended through:

Drug effect profiling (did the regimen produce anti-aldosterone activity in the claimed context?)
Clinical endpoints and biomarkers consistent with antiandrogenic and antialdosterone activity
Labeling/inducement that ties the use to the triad outcomes

What dosing and patient-population limitations exist in US 5,569,652?

Dose ranges (claims 6-7 and 12, 24, 27)

Claim 1 is not limited to a specific dose in the text you provided, but dependent claims are:

Claim 6: 0.5–50 mg/day
Claim 7: 1–10 mg/day

In combination with estrogen:

Claim 12: dihydrospirorenone 0.5–50 mg/day and estrogen as estradiol valerate equivalent 0.5–4.0 mg/day
Claim 24: dihydrospirorenone 1–10 mg/day
Claim 27: dihydrospirorenone 0.5–50 mg/day and estrogen as 0.02–0.04 mg/day of 17α-ethynylestradiol

Implications:

Competitors dosing outside 0.5–50 mg/day would avoid at least those narrower dependent claims, but could still implicate claim 1 if the regimen nonetheless achieves the triad at “an amount… effective.”
For combinations, the estrogen dose/species limitations can be used to map design-arounds.

Age and hormonal-state limits (claims 2, 5, 4, 19)

Claim 2: method of claim 1 where patient is in premenopause
Claim 5: method of claim 1 where patient is in menopause
Claim 4: patient age 35–55
Claim 19: claim 11 with patient age 35–55
Claim 23: claim 11 where patient is in menopause

These create “use-code” pockets for generic and challenger designs:

If a competitor positions a use outside premenopause/menopause or outside the 35–55 band, they can attempt to avoid dependent-claim narrowing (while still facing claim 1/11 if the underlying triad requirement is met).

Medical condition/profile limitations (claims 3, 8, 9, 10, 13-16, 25-26)

Examples of dependent limitations:

Claim 3: premenopause; stabilization of menstruation
Claims 8-10, 14, 16, 25: patient predisposed to androgenization symptoms and/or suffers from or is predisposed to high blood pressure
Claims 13, 15, 16: patient suffers from symptoms of androgenization; premenopause; plus high blood pressure where included
Claim 26: premenopause; stabilization of menstruation

Implications:

For monotherapy, these are added limitations (dependent), not in claim 1.
For combination therapy, these conditions can further tether infringement proof to specific clinical indications and patient categories.

What estrogen provisions materially expand or constrain claim 11 (and its dependents)?

Claim 11 requires an estrogenic compound in addition to dihydrospirorenone. Dependent claims specify estrogen identity:

Natural vs synthetic estrogen

Claim 17: estrogenic compound is a synthetic estrogen
Claim 18: estrogenic compound is a natural estrogen
Claim 20: claim 11 where estrogen is synthetic
Claim 21: claim 12 where estrogen is natural

A specific estrogen example

Claim 22: estrogenic compound is 17α-ethynylestradiol
Claim 27: 17α-ethynylestradiol dose equivalent 0.02–0.04 mg/day
Claim 12: estradiol valerate equivalent 0.5–4.0 mg/day

Functional effect: the estrogen component is tied to contraceptive effect in claim 11. Even if a competitor matches dihydrospirorenone triad pharmacodynamics, the combination portion must be designed so that the regimen also achieves the claim 11 requirement of contraceptive effect, unless they remain within claim 1 territory (monotherapy).

How broad is the overall claim coverage across product forms and routes?

The claims as provided are directed to methods of administering dihydrospirorenone. They do not include explicit:

dosage form (tablet, patch, etc.)
route (oral, transdermal)
pharmacokinetic profile
manufacturing steps

That absence means the scope is primarily defined by:

active ingredient identity (dihydrospirorenone)
patient hormonal state (premenopause/menopause)
functional outcomes (triple triad)
optional inclusion of estrogen and contraception requirement

For design-around analysis, route and dosage form are likely secondary unless they affect the ability to achieve the triad “simultaneously.”

Which claim elements create the strongest litigation friction for competitors?

Anti-aldosterone effect (functional triad)
- This is the hardest element to substitute away if the competing regimen lacks a true functional antialdosterone effect.
“Simultaneously achieving”
- Disputes can arise over whether the three effects are achieved at the same time under the competitor’s intended use and dosing.
Premenopause/menopause restriction
- If a challenger markets for other indications or other life stages, dependent claims can be narrowed away. Claim 1/11 still remain if the “in need thereof” patient selection and hormonal state line up.
Combination contraception requirement in claim 11
- Even if dihydrospirorenone produces triad effects, the presence of estrogen is coupled to contraceptive function. This can matter in labeling and inducement.

How much of the claim set is dedicated to combination therapy vs monotherapy?

From the text provided:

Monotherapy anchor: claim 1 (and claim 2, 3, 4, 5, 6, 7, 8, 9, 10)
Combination anchor: claim 11 (and claims 12, 13-27)

Dependent claims 11-27 are heavily skewed toward:

specifying estrogen type (natural/synthetic)
specifying estrogen identity (17α-ethynylestradiol)
specifying estrogen dose equivalents
specifying patient subprofiles (androgenization, high blood pressure)
specifying hormonal sub-stage (premenopause vs menopause)
specifying menstrual stabilization

So, the patent landscape is best viewed as:

a core monotherapy triad protection
plus a combination contraception + triad layer

What does the expiration timeline likely look like for US 5,569,652?

No filing date, priority date, or term adjustment data was included in the input. Without those dates, the exclusivity/expiration cannot be calculated precisely here.

What is the likely competitive relevance to drospirenone-like oral contraceptive and hormone-regimen markets?

The patent is centered on dihydrospirorenone, a compound conceptually adjacent to spirorenone/drospirenone pharmacology (progestational and antimineralocorticoid activity). Even without mapping to a specific commercial product in the provided record, the claim structure indicates it targets:

women in premenopause or menopause
with androgenization symptoms and/or hypertension risk
seeking contraceptive and hormonal symptom control

This claim positioning directly affects:

generic “skin in the game” design-around strategies (avoid the triad functional package)
label alignment in FDA submissions for comparable regimens
litigation leverage for patent holders (functional triad language can be paired with bioassay and clinical biomarker evidence)

Key claim-to-design-around mapping (practical freedom-to-operate lens)

Competitor design choice	Potential claim impact
Use dihydrospirorenone but do not aim for anti-aldosterone effect	Can challenge satisfaction of the triad; may avoid claims 1 and 11 if antialdosterone effect is absent
Use dihydrospirorenone in non-premenopause/non-menopause populations	Avoids premenopause/menopause limitation; dependent claim narrowing may be avoided; claim 1/11 may be avoided if patient selection is outside the defined hormonal stage
Use dihydrospirorenone but outside 0.5–50 mg/day	Avoid dependent dose-limited claims (6, 7, 12, 24, 27); claim 1 may still apply if an “effective amount” achieves triad
Add an estrogen but not for contraceptive effect	For claim 11, absence of “contraceptive effect” can be a material gap
Use different estrogen chemistry or dosing not matching dependents	May avoid narrower dependent claims (12, 22, 27), while claim 11 can still apply if the estrogen qualifies as “an estrogenic compound” and contraception + triad occur
Target only androgenic symptom control or only BP control	Does not meet the “simultaneously achieving” triad requirement

What you can infer about patent strength from claim structure alone

The independent claims are broad by functional effects (gestagenic, antiandrogenic, antialdosterone) and by hormonal stage (premenopause/menopause).
The claim set adds “knobs” through dependents: dose bands, age, menstrual stabilization, androgenization symptoms, hypertension predisposition, and specific estrogen embodiments.
The functional triad requirement can be a litigation fulcrum; it is both a scope-defining feature and a potential invalidity/indefiniteness attack surface in some jurisdictions, but the record you provided does not include the specification, prosecution history, or cited prior art to evaluate validity.

Key Takeaways

US 5,569,652 protects methods using dihydrospirorenone to achieve a triple functional triad: gestagenic + antiandrogenic + antialdosterone, for female patients in premenopause or menopause.
Claim 11 adds a combination layer: dihydrospirorenone + an estrogenic compound to achieve contraceptive effect plus the same triple triad.
Dependent claims narrow by dose (0.5–50 mg/day; 1–10 mg/day), age (35–55), menstrual stabilization, androgenization symptoms, and hypertension predisposition/suffering.
Estrogen dependents constrain embodiments with estradiol valerate equivalents and 17α-ethynylestradiol dose bands, while still leaving claim 11 broad to any “estrogenic compound” achieving the claimed contraceptive and triad outcomes.

FAQs

Does US 5,569,652 cover dihydrospirorenone without estrogen?

Yes. Claim 1 covers administering dihydrospirorenone alone to achieve the triple triad during premenopause or menopause.

What estrogen types are explicitly claimed with dihydrospirorenone in combination therapy?

Natural and synthetic estrogens are covered via dependent claims; 17α-ethynylestradiol and estradiol valerate equivalent dosing are specifically exemplified in the provided claim set.

What dose ranges are most relevant for claim 1/11 infringement risk?

For dependent dosing, the key bands are 0.5–50 mg/day and 1–10 mg/day. Combination dependents also specify estrogen dose equivalents.

Do symptoms like androgenization and hypertension limit the independent claims?

No. The androgenization and hypertension profile limitations appear in dependent claims (8-10, 13-16, 25), not in claim 1 or claim 11 as presented.

Is menstrual stabilization protected only for premenopause?

Yes in the dependent claims provided: menstrual stabilization appears linked to premenopause (claims 3 and 26).

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Germany	39 16 112.9	May 16, 1989

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	0398460	⤷ Start Trial	91065	Luxembourg	⤷ Start Trial
European Patent Office	0398460	⤷ Start Trial	SPC/GB04/032	United Kingdom	⤷ Start Trial
European Patent Office	0398460	⤷ Start Trial	CA 2001 00011	Denmark	⤷ Start Trial
European Patent Office	0398460	⤷ Start Trial	300221	Netherlands	⤷ Start Trial
European Patent Office	0398460	⤷ Start Trial	C00398460/01	Switzerland	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 5,569,652

Summary for Patent: 5,569,652